

Date: 30th June, 2020

To, The Manager, Dept of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, Scrip Code: 511 509

Dear Sir/Madam,

Sub: Audited Financial Results for the 4th quarter and year ended 31stMarch, 2020.

With reference to the above subject, please find enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

- Audited Consolidated and Standalone Financial Results for the 4th quarter and year ended 31st March, 2020, these results were approved by the Board of Directors at their meeting held on Tuesday, 30th June, 2020;
- 2. Auditors Report on Consolidated and Standalone Financial Results for the 4th quarter and year ended 31st March, 2020 issued by the Statutory Auditors; and
- 3. Declaration pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulation, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

A.Karthik

Company Secretary

	AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AN	TEAR ENDED 3151	MARCH, 2020		Rs. i	n Lacs	
S.No.	PARTICULARS		QUARTER ENDED			YEAR ENDED	
	- Anneadana	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019	
1	P	Refer Note#2	Un-Audited	Refer Note#2	Audited	Audited	
11	Revenue from operations Other Income	1,435.53	1410.70	1376.50	5535.22	5583.35	
111	Total Income	2.39	0.00		5.32	1.2	
IV		1437.92	1410.70	1376.50	5540.54	5584.56	
1900	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	(85.64)	(17.99)	79.31	(234.23)	-65.01	
	b) Consumption of Raw materials	0.00	0.00	0.00	0.00	0.00	
	c) Purchase of traded goods	359.93	206.29	218.33	1089.97	1240.92	
	d) Employees Cost	258.77	263.46	300.61	999.77	957.8	
	e) Depreciation and amortisation	118.84	145.42	126.44	517.16	505.77	
	f) Finance Cost	79.34	67.87	63.52	309.84	264.09	
	g)Administrative Expenditure	780.44	579.61	524.30	2432.70	2119.96	
43		tal 1510.67	1244.66	1312.51	5115.20	5023.53	
V	Profit Before Tax & Exceptional Item (III-IV)	(72.75)	166.04	64.00	425.34	561.03	
	Expceptional Item	0.00	0.00	378.36	0.00	378.36	
VI	Profit Before Tax	(72.75)	166.04	(314.36)	425.34	182.67	
VII	Tax Expense						
	a. Current Tax	(15.79)	45.30	(80.60)	112.33	37.6	
	b. Deffered tax	(16.38)	(10.45)	63.93	(131.14)	-79.93	
	Total Tax Expense	(32.17)	34.85	(16.66)	(18.82)	(42.33)	
	Net Profit After Tax (V-VI)	(40.58)	131.19	(297,70)	444.15	225.00	
VIII	Minority Interest	0.00	0.00	0.00	0.00	0.00	
EX	Other Comprehensive Income					0.00	
	a Items that will be reclassified to profit or loss (Net of Tax)	0.00	0.00	0.00	0.00	0.00	
×	Total other Comprehensive Income(VII+VIII+IX)	(40,58)	131.19	(297.70)	444.15	225.00	
XE	Paid Up Share Capital (Face value of Rs. 10/-) (In lakh Units)	1288.75	1288.75	1235.05	1288.75	1235.05	
XII	Earnings per equity share:					1255.03	
	1)Basic	(0.31)	1.02	(2.41)	3.45	1.82	
	2)Diluted	(0.31)	1.02	(2.33)	3.45	1.76	

Date

30/06/2020

Place

Hyderabad

M. Kalyan Ram Whole Time Director DIN: 02012580

Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email: investors@vivobio.com, Phone: 040-23313288, Website: www.vivobio.com, CIN: L65993TG1987PLC007163

	AUDITED STANDALONE FINANCIAL RESULTS FOR THE QTR A	THE PERMIT	Sast mirately E	1	9500000000	s. in Lacs
S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Refer Note#2	Un-Audited	Refer Note#2	Audited	Audited
1	Revenue from operations	1,435.53	1410.70	1376.50	5535,22	5583.34
11	Other Income	2.39	0.00	0.00	5.32	1.21
111	Total Income	1437.92	1410.70	1376.50	\$540.54	5584.55
IV	Expenses					
	a) Increase/(decrease) in stock in trade and WIP	(86.64)	(17.99)	79.31	(234.23)	-65.01
	b) Consumption of Raw materials	0.00	0.00	0.00	0.00	0.00
	c) Purchase of traded goods	359.93	206.29	218.33	1089.97	1240.92
	d) Employees Cost	258.78	263.46	300.61	999.77	957.8
	e) Depreciation and amortisation	118.85	145.42	126.44	517.16	505.77
	f) Finance Cost	79.34	67.87	63.52	309.84	264.09
	g)Administrative Expenditure	780.23	579.61	524.30	2432.49	2119.96
	Total	1510.48	1244.66	1312.51	5114.99	5023.53
V	Profit Before Tax (III-IV)	(72.56)	166.04	64.00	425.55	561.02
	Expceptional Item	0.00	0.00	378.36	0.00	378.36
VI	Profit Before Tax	(72.56)	166.04	(314.36)	425.55	182.66
VII	Tax Expense					
	a. Current Tax	(15.79)	45.30	(80.60)	112.33	37.6
	b. Deffered tax	(16.38)	(10.45)	63.93	(131.14)	-79.93
	Total Tax Expense	(32.17)	34.85	(297.70)	(18.82)	-42.33
	Net Profit After Tax (V-VI)	(40.39)	131.19	(16.66)	444.36	224.99
VIII	Other Comprehensive Income					
	a.Items that will be reclassified to profit or loss (Net of Tax)	¥:	0.00	0.00	0.00	0.00
1X	Total other Comprehensive Income(VII+VIII+IX)	(40.39)	131.19	(297.70)	444.36	22
Х	Paid Up Share Capital (Face value of Rs.10/-) (in lakh Units)	1288.75	1288.75	1235.05	1288.75	1235.05
XI	Earnings per equity share:					
	1)Basic	(0.31)	1.02	(2.41)	3.45	1,82
	2)Diluted	(0.31)	1.02	(2.33)	3.45	1.70

Date 30/06/2020

Place Hyderabad

M. Kalyan Ram Whole Time Director DIN: 02012580

Vivo Bio Tech Ltd. Your Drug Discovery Partner

Notes

- The above Audited Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30th June, 2020.
- The figures for the quarter ended 31st March 2020 and 31st March 2019 are the balancing
 figure between the audited figures of the full financial year and the published year-to-date
 figures upto the 3rd quarter of respective financial years which were subject to Limited
 Review by the Statutory Auditor of the Company.
- The Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
- The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
- 6. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Place: Hyderabad Date: 30th June, 2020

For Vivo Bio Tech Limited

Hyderabac

M. Kalyan Ram

Whole Time Direct

DIN: 02012580

	Consolidated Cash Flow Statement for the Year Ended 3	As at	0	Rs. In Lacs	
	Particulars			As at	
		31.03.2020		31.03.2019	
Α.	Cach Flour fram C	Audited		Audited	
E.W.	Cash Flow from Operating Activities:				
	Net Profit/ (Loss) before taxation and extraordinary items		425		
	Adjustments for:		44.0	182	
	Depreciation		517	****	
	Amortised Expenses		011	506	
	Interest expenses		310	***	
	Operating Profit before Working Capital Changes			264	
	Working Capital Changes		1,252	952	
	Trade and other receivables Including Inventory		(15.4)		
	Trade and Other payables		(154)	(68	
	Cash Generated from Operations			(740	
	Interest paid		1,152 310	144	
	Taxation for the year		(19)	264	
	Net Cash from Operating Activities		862	(42)	
3.	Cash Flow from Investing Activities:		802	(77)	
	Purchase of Fixed Assets	/4.0221			
	Investment		(1,023)	(353)	
	Net Cash used in Investing Activities		(1.033)		
	Cash Flow From Financial Activities:		(1,023)	(353)	
	Proceeds from Equity Shares		121		
	Net Proceeds from Long Term Borrowings		78	572	
	Net Cash used in Financing Activities		209	(500)	
	Net increase in cash and cash equivalents			72	
	Cash and Cash equivalents as at Beginning of the Year		48	(358)	
	Cash and Cash equivalents as at 31.03.2020		57	415	
	CONTRACTOR OF STANDARD AND STAN		105	57	

Hyderabac

Date

30/06/2020

Place

Hyderabad

M. Kalyan Ram Whole Time Director

DIN: 02012580

Standalone Cash Flow Statement for the Year Ended Particulars		As at		Rs. In Lacs	
		31.03.2020		31.03.2019	
10				Audited	
A.	Cash Flow from Operating Activities:			Addited	
	Net Profit/ (Loss) before taxation and extraordinary items		426	183	
	Adjustments for:			103	
	Depreciation		517	506	
	Amortised Expenses		2		
	Interest expenses		310	264	
	Operating Profit before Working Capital Changes		1,253	953	
	Working Capital Changes		1,233	900	
	Trade and other receivables Including Inventory		(242.56)	(69	
	Trade and Other payables		53	(740	
	Cash Generated from Operations		1,063	143	
	Interest paid		310	264	
	Taxation for the year		(19)	(42	
	Net Cash from Operating Activities		773		
В.	Cash Flow from Investing Activities:		,,,	(78	
	Purchase of Fixed Assets		(707)	(353	
	Investment		(1)	(555)	
	Net Cash used in Investing Activities		(708)	(353)	
C.	Cash Flow From Financial Activities:		(,,,,,,	(555)	
	Proceeds from Equity Shares		131	570	
	Net Proceeds from Long Term Borrowings		(149)	(500)	
	Net Cash used in Financing Activities		(18)	70	
	Net increase in cash and cash equivalents		46	(361)	
	Cash and Cash equivalents as at Beginning of the Year		53	415	
	Cash and Cash equivalents as at 31.03.2020		99	54	

Date

30/06/2020

Place

Hyderabad

M. Kalyan Ram Whole Time Directo

DIN: 02012580

Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email: investors@vivobio.com, Phone: 040-23313288, Website: www.vivobio.com, CIN: L65993TG1987PLC007163.

		Stand	dalana		March, 2020 Rs. In Lacs Standalone Consolidated				
	8251 871 37	2.0	aaione	Consolidated					
SI.No	Particulars	31.03.2020	31.03.2019	31.03.2020	31.03.2019				
		Audited	Audited	Audited	Audited				
10	ASSETS			The same of the sa	riddited				
	Non-Current Assets	l (
	Fixed Assets		N 11.3						
			10.8						
	Property, Plant and Equipment	2,525.26	2,461.01	2,861.28	2,480				
	Capital Work-In-Progress	15.36	6.60	15.36	OURSEASTING.				
	Intangible Assets	637.48	520.81	637.48	520				
	etat-t-k				321				
-	Financial A ssets			l l	()				
	Non-Current Investments	4.00	3,00						
	Long Term Loans and Advances	8			11				
	Other Non Current Assets	5.89	9.74	7.83	1.				
1	Total Non-Current Assets	3,187.98	3,001,17	3,521.94	3,019				
	Current Assets		37.44.67	3,321.34	3,019				
11	Inventories	1,057.87	823.63	1 052 02					
	Financial Assets	7/10/10/00	063,03	1,057.87	823				
- 1	Trade Receivables	1,048.21		27.000.000					
- 1	Cash and cash equivalents	99.05	841.00	1,048.21	841				
- 1	Short term loans and advances	536.91	52.76	102.86	56				
	Other current assets	57.24	734.25	425.97	712				
- 1	Total Current Assets	7-2-03/20/20/20/20	54.93	57.24	54				
1	TOTAL ASSETS	2,799.28	2,506.57	2,692.15	2,488				
- 1	-	5,987.27	5,507.74	6,214.09	5,507				
11	EQUITY AND LIABILITIES								
	Equity			1					
	Equity Share Capital								
- 1	Other Equity	1,288.75	1,235.05	1,288.75	1,235.				
- 1	Money Received Against Share Warrants	2,014.95	1,463.19	2,013.66	1,462.				
- 1		- 75	30.00	1740	30.				
1,	Total Equity	3,303.70	2,728.24	3,302.41	2,727.				
1									
100	Non Current liabilities	1							
ľ	Financial Liabilities								
- 1	Borrowings	741.04	889.94	968.74	890.				
	Defered Tax Liabilities(Net)	(154.83)	(23.69)	(154.83)	(23.				
- 1	Long term provisions	41.62	35.86	41.62	35.				
1	Total Non Current Liabilities	627.83	902.11	855.53	902.				
C	Current Liabilities			170.00	302.				
F	Financial Liabilities		1/4						
	Borrowings	1,467.48	1,277.23	1,467.48	1,277.				
	Trade Payable & Other Current Liabilities	391.37	490.02	391.37	490.0				
	Provisions	196.89	110.15	197.31	110.				
- 6			0.99203.0		110.				
- 1	Toatal Current Liabilities	2,055.74	1,877.40	2,056.15	1,877.6				
	Total Equity & Liabilities	5,987.27	5,507.74	6,214.09	5,507.5				
e: Hyde		For Vivo Bio Tech Ltd	BIO		3,5071.				
: 30th J	June, 2020	men !	2/4m (c)						
	194	(F	Hyderabad CI						
		1. Kalyan Ram	NY NY						
	1	Whole Time Director							

Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email: investors@vivobio.com, Phone: 040-23313288, Website: www.vivobio.com, CIN: L65993TG1987PLC007163.



PCN & ASSOCIATES

CHARTERED ACCOUNTANTS Plot No. 12, "N Heights" Ground Floor, Software Layout Unit Cyberabad, Hyderabad - 500 081. Tel. : (91-40) 2311 9499

E-mail: pcnassociates@yahoo.com

INDEPENDENT AUDITOR'S REPORT

THE BOARD OF DIRECTORS OF VIVO BIO TECH LIMITED

Report on the audit of the Consolidated Financial Results

Opinion


We have audited the accompanying Statement of Consolidated Financial Results of M/s VIVO BIO TECH LIMITED ("Holding company") and its subsidiary (holding company and its subsidiary together referred to as "the Group"), for the quarter ended 31st March 2020 and for the period from 01-04-2019 to 31-03-2020 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

- a. In our opinion and to the best of our information and according to the explanations given to us, these quarterly consolidated financial results as well as the consolidated year to date financial results: includes the results of the following entity:
 - (i) Vivo Bio Labs Private Limited
 - (ii) Vivo Bio Discovery Services Private Limited
 - (iii) Surlogic Life Consultancy Private Limited
 - (iv) Vivo Bio Consulting Services Private Limited (Formerly Known as Donakanti Consultancy Services Private Limited)
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit and other comprehensive income) and other financial information of the Group for the quarter ended 31st March 2020 and for the period from 01-04-2019 to 31-03-2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered





E-mail: pcnassociates@yahoo.com

Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and unaudited interim Financial Statements furnished to us by the Board of Directors referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results


These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive incom- and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.





Tel. : (

: (91-40) 2311 9499

E-mail: pcnassociates@yahoo.com


Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from frat 1 is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.





E-mail: pcnassociates@yahoo.com

 Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

• Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The consolidated Financial Results include the Audited Financial Results of four Subsidiaries, whose interim Financial Statements reflect Group's share of total assets before elimination of Rs. 3,41,76,826/- as at 31st March 2020, Group's share of total revenue of Rs. Nil and Group's share of Net loss after tax of Rs. 20,739/- for the period from 01-04-2019 to 31-03-2020, as considered in the consolidated Financial Results. These interim financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.





PCN & ASSOCIATES

CHARTERED ACCOUNTANTS Plot No. 12, "N Heights" Ground Floor, Software Layout Unit Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail: pcnassociates@yahoo.com

Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other Auditors.

For PCN & Associates, Chartered Accountants,

Firm's Registration Number: 016

NAVEEN Digitally signed by NAVEEN MADIVADA Date: 2020.06.30 15:46:51 +05'30'

M Naveen Partner

Membership No:237316

UDIN: 20237316AAAADO4159

Place: Hyderabad Date: 30-06-2020

E-mail: pcnassociates@yahoo.com

TO THE BOARD OF DIRECTORS OF VIVO BIO TECH LIMITED

Report on the audit of the Standalone Financial Results

Opinion:

We have audited the accompanying standalone quarterly financial results of M/s. **VIVO BIO TECH LIMITED** for the quarter ended 31st March, 2020 and the year to date results for the period from 01-04-2019 TO 31-03-2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2020 as well as the year to date results for the period from 01-04-2019 to 31-03-2020.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



E-mail : pcnassociates@yahoo.com

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.



E-mail: pcnassociates@yahoo.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.



PCN & ASSOCIATES CHARTERED ACCOUNTANTS Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For PCN & Associates, Chartered Accountants, Firm's Registration Number

NAVEEN MADIVADA Date: 2020.06.30 13:07:51 +05'30'

Digitally signed by NAVEEN MADIVADA

M Naveen Partner

Membership No:237316

UDIN: 20237316AAAADP7442

Place: Hyderabad Date: 30-06-2020

Date: 30th June, 2020

To, The Manager, Dept of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, Scrip Code: 511 509

Dear Sir/Madam,

Sub: Declaration for unmodified opinion pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulations, 2015.

We hereby declare that the Statutory Auditors of the Company i.e., M/s. P C N & Associates, Chartered Accountants (Firm Reg No. 016016S) have issued unmodified opinion on financial results of the company for the quarter and financial year ended on 31st March, 2020.

The above declaration is issued in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD /56/2016 dated 27th May, 2016.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

Merch

Kalyan Ram Mangipudi Whole Time Director DIN: 02012580

